ABX464 (obefazimod) for patients with COVID-19 at risk for severe disease: miR-AGE, a randomized, double-blind placebo-controlled trial (2023)
- Authors:
- USP affiliated authors: GIAVINA-BIANCHI JUNIOR, PEDRO FRANCISCO - FM ; KALIL FILHO, JORGE ELIAS - FM
- Unidade: FM
- DOI: 10.1016/j.jacig.2023.100140
- Subjects: CORONAVIRUS; COVID-19; PLACEBOS
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Publisher place: Philadelphia
- Date published: 2023
- Source:
- Título: Journal of allergy and clinical immunology: global
- ISSN: 2772-8293
- Volume/Número/Paginação/Ano: v. 2, n. 4, article ID 100140, p, 2023
- Este periódico é de acesso aberto
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: green
-
ABNT
GIAVINA-BIANCHI JÚNIOR, Pedro Francisco et al. ABX464 (obefazimod) for patients with COVID-19 at risk for severe disease: miR-AGE, a randomized, double-blind placebo-controlled trial. Journal of allergy and clinical immunology: global, v. 2, n. 4, 2023Tradução . . Disponível em: https://observatorio.fm.usp.br/handle/OPI/58602. Acesso em: 01 jan. 2026. -
APA
Giavina-Bianchi Júnior, P. F., Cua, E., Risso, K., Mondain, V., Vissian, A., Joie, C., et al. (2023). ABX464 (obefazimod) for patients with COVID-19 at risk for severe disease: miR-AGE, a randomized, double-blind placebo-controlled trial. Journal of allergy and clinical immunology: global, 2( 4). doi:10.1016/j.jacig.2023.100140 -
NLM
Giavina-Bianchi Júnior PF, Cua E, Risso K, Mondain V, Vissian A, Joie C, Pouletty P, Gineste P, Ehrlich HJ, Kalil Filho JE. ABX464 (obefazimod) for patients with COVID-19 at risk for severe disease: miR-AGE, a randomized, double-blind placebo-controlled trial [Internet]. Journal of allergy and clinical immunology: global. 2023 ; 2( 4):[citado 2026 jan. 01 ] Available from: https://observatorio.fm.usp.br/handle/OPI/58602 -
Vancouver
Giavina-Bianchi Júnior PF, Cua E, Risso K, Mondain V, Vissian A, Joie C, Pouletty P, Gineste P, Ehrlich HJ, Kalil Filho JE. ABX464 (obefazimod) for patients with COVID-19 at risk for severe disease: miR-AGE, a randomized, double-blind placebo-controlled trial [Internet]. Journal of allergy and clinical immunology: global. 2023 ; 2( 4):[citado 2026 jan. 01 ] Available from: https://observatorio.fm.usp.br/handle/OPI/58602 - Intradermal test is a relevant biomarker of the outcome of rapid desensitizationin penicillin allergy
- Atopy Is Associated with Age at Asthma Onset in Elderly Patients
- Drug-Induced Anaphylaxis
- Associated factors with sensitisation and allergy to latex
- Allergy To Betalactams In Brazil: Placebo Effect Or Misdiagnosis?
- Mycoplasma pneumoniae infection induces asthma onset
- Terapia monoclonal nas doeças alérgicas
- Introdução
- New associations between HLA genotypes and asthma phenotypes
- BAT in the diagnosis of drug allergy: a novel tool in clinical daily practice?
Informações sobre o DOI: 10.1016/j.jacig.2023.100140 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
